MITOLACTOL


Synonyms	Dibromdulcit Dibromodulcitol Elobromol Mitolactol NCI-C04795 NSC-104800
Status
Molecule Category	UNKNOWN
UNII	LJ2P1SIK8Y
EPA CompTox	DTXSID8020414


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	VFKZTMPDYBFSTM-GUCUJZIJSA-N
Smiles	O[C@H]([C@H](O)[C@@H](O)CBr)[C@H](O)CBr
InChI	InChI=1S/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4+,5+,6-

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C6H12Br2O4
Molecular Weight	307.97
AlogP	-0.78
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	5.0
Polar Surface Area	80.92
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	12.0

Related Entries

Cross References

Resources	Reference
ChEBI	135311
ChEMBL	CHEMBL2104612
DrugBank	DB12916
DrugCentral	857
FDA SRS	LJ2P1SIK8Y
PubChem	5284380
SureChEMBL	SCHEMBL8455
ZINC	ZINC000004216958

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).